Subtyping of triple-negative breast cancer: Implications for therapy

Cancer

Volumn 121, Issue 1, 2015, Pages 8-16

  Abramson, Vandana G ^a   Lehmann, Brian D ^a   Ballinger, Tarah J ^a   Pietenpol, Jennifer A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Clinical trials; Subtyping triple negative breast cancer; Targeted therapies; Triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTHRACYCLINE; BEVACIZUMAB; BICALUTAMIDE; BRCA1 PROTEIN; BUPARLISIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; GEMCITABINE; GROWTH FACTOR; INIPARIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; VELIPARIB; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; MOLECULAR BIOLOGY; MONOTHERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; CLINICAL TRIAL (TOPIC); FEMALE; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84919383828     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28914     Document Type: Review

References (52)

1. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434.
2. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295: 2492-2502.
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
4. Makretsov NA, Huntsman DG, Nielsen TO, et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res. 2004;10:6143-6151.
5. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376.
6. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49:22-34.
7. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and longterm survival [serial online]. Breast Cancer Res. 2007;9:R4.
8. Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 2005;11:4003-4011.
9. Subhawong AP, Subhawong T, Nassar H, et al. Most basal-like breast carcinomas demonstrate the same Rb-/p161 immunopheno-type as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol. 2009; 33:163-175.
10. Reis-Filho JS, Savage K, Lambros MB, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol. 2006;19:999-1009.
11. Rakha EA, Ellis IO, Reis-Filho JS. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol. 2008;21:1060-1061; author reply 1061-1062.
12. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer. 2008;123:236-240.
13. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27: 1160-1167.
14. de Ronde JJ, Hannemann J, Halfwerk H, et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat. 2010;119:119-126.
15. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
16. Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009;15:441-451.
17. Gewinner C, Wang ZC, Richardson A, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 2009;16:115-125.
18. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65:2554-2559.
19. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395-399.
20. Matros E, Wang ZC, Lodeiro G, et al. BRCA1 promoter methyla-tion in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005;91:179-186.
21. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer. 2004;4:814-819.
22. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2010;16:6159-6168.
23. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-2767.
24. Lehmann B, Pietenpol J. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142-150.
25. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615-2623.
26. Vaklavas C, Abramson VG, Lin NU, et al. TBCRC 019: an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC) [abstract]. J Clin Oncol. 2013;31(May 20 suppl). Abstract 1052.
27. O'Shaughnessy J, Miles D, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer [abstract]. Breast Cancer Res Treat. 2007;106(suppl 1). Abstract 308.
28. Baselga J, Gomez P, Greil R, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with meta-static triple-negative breast cancer. J Clin Oncol. 2013;31:2586-2592.
29. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to pol-y(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109-8115.
30. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadju-vant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28: 1145-1153.
31. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008;108:289-296.
32. Von Minckwitz G, Schneeweiss A, Salat C, et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto) [abstract]. J Clin Oncol. 2013;31(suppl). Absract 1004.
33. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Paper presented at: The 2013 San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, Texas. Abstract S5-01.
34. Mayer IA, Jovanovic B, Abramson VG, et al. A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC). Poster presented at: The 2013 San Antonion Breast Cancer Symposium; December 10-14, 2013; San Antonio, Texas.
35. Telli M, Jensen K, Abkevich V, et al. Homologous recombination deficiency (HRD) score predicts pathologic response following neo-adjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC) [abstract]. Cancer Res. 2012; 72(24 suppl 3).
36. Johnson N, Li YC, Walton ZE, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med. 2011;17:875-882.
37. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) poly-merase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235-244.
38. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-134.
39. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434:917-921.
40. Tutt A, Ashworth A. Can genetic testing guide treatment in breast cancer? Eur J Cancer. 2008;44:2774-2780.
41. Lord CJ, Garrett MD, Ashworth A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res. 2006;12:4463-4468.
42. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol. 2005;5:388-393.
43. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852-861.
44. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205-214.
45. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcita-bine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) [abstract]. J Clin Oncol. 2011;29(suppl). Abstract 1007.
46. Tell ML, Jensen KC, Kurian AW, et al. PrECOG 0105: final efficacy results from a phase II study of gemcitabine and carboplatin plus iniparib (BSI201) as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer. J Clin Oncol. 2013; 31(suppl). Abstract 1003.
47. Rugo HS, Olopade O, DeMichele A, et al. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 trial. Paper presented at: The 2013 San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, Texas. Abstract S5-02.
48. Masuda H, Baggerl KA, Wang Y, et al. Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer [abstract]. J Clin Oncol. 2013;31(suppl). Abstract 1005.
49. Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19:5505-5512.
50. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472-2478.
51. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084-6091.
52. Ibrahim YH, Garcia-Garcia C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2: 1036-1047.